SLC5A2 and heart failure: The addition of some criteria aligns with recent guidelines updates and significant advancements in clinical practice (e.g. SGLT2 inhibitors, the distinction between heart failure with preserved or reduced ejection fraction, vaccination) which is a welcome development.